All data are based on the daily closing price as of April 28, 2025
c
CHO Pharma
6586.TWO
1.36 USD
0.04
+3.03%
Overview
Last close
1.36 usd
Market cap
290.06M usd
52 week high
2.41 usd
52 week low
1.18 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
2694.5254
Price/Book Value
3.2934
Enterprise Value
206.89M usd
EV/Revenue
1875.8743
EV/EBITDA
-34.5511
Key financials
Revenue TTM
110289.59 usd
Gross Profit TTM
52680.22 usd
EBITDA TTM
-7.32M usd
Earnings per Share
-0.03 usd
Dividend
N/A usd
Total assets
92.60M usd
Net debt
-2.95M usd
About
CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in Taipei City, Taiwan.